Developments in drugs for the treatment of chronic obstructive pulmonary disease

Expert Review of Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 365-377

  Mui, Tammy S Y ^a   Man, S F Paul ^a   Sin, Don D ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Anti inflammatory; Chronic obstructive pulmonary disease; Inflammation; Mediator antagonist; Protease inhibitor

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; AMINOPHYLLINE; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CARMOTEROL; CICLESONIDE; CORTICOSTEROID; ETALOCIB; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; GLYCOPYRRONIUM BROMIDE; GSK 159797; GSK 233705; GW 642444; INDACATEROL; INFLIXIMAB; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; PLACEBO; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNINDEXED DRUG;

BIOMASS; BONE DEMINERALIZATION; BRONCHODILATATION; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG MEGADOSE; GENETIC DISORDER; GLAUCOMA; HUMAN; IMMUNOPATHOLOGY; INFECTION; LYMPHOMA; MORTALITY; MYOPATHY; NONHUMAN; OROPHARYNX CANDIDIASIS; PATHOGENESIS; POLLUTION; PROGNOSIS; PROTEIN TARGETING; REVIEW; RISK FACTOR; SKIN BRUISING; UNSPECIFIED SIDE EFFECT;

EID: 46149083238     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.3.365     Document Type: Review

References (115)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064), 1498-1504 (1997).
2. Barnes PJ. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343(4), 269-280 (2000).
3. Rabe KF, Hurd S, Anzueto A et al. Globa strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176(6), 532-555 (2007).
4. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir. Care 48(12), 1185-1191 (2003).
5. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 113(4 Suppl.), S235-S241 (1998).
6. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 152(5 Pt 2), S77-S121 (1995).
7. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 362(9387), 847-852 (2003).
8. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 166(5), 675-679 (2002).
9. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142(4), 233-239 (2005).
10. Murray RP, Connett JE, Rand CS, Pan W, Anthonisen NR. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev. Med. 35(4), 314-319 (2002).
11. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290(17), 2301-2312 (2003).
12. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 93(3), 391-398 (1980).
13. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N. Engl. J. Med. 291(15), 755-758 (1974).
14. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109(5), 571-577 (2002).
15. Green GM, Jakab GJ, Low RB, Davis GS. Defense mechanisms of the respiratory membrane. Am. Rev. Respir. Dis. 115(3), 479-514 (1977).
16. Simani AS, Inoue S, Hogg JC. Penetration of the respiratory epithelium of guinea pigs following exposure to cigarette smoke. Lab. Invest. 31(1), 75-81 (1974).
17. Jones JG, Minty BD, Lawler P, Hulands G, Crawley JC, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1(8159), 66-68 (1980).
18. Hulbert WC, Walker DC, Jackson A, Hogg JC. Airway permeability to horseradish peroxidase in guinea pigs: the repair phase after injury by cigarette smoke. Am. Rev. Respir. Dis. 123(3), 320-326 (1981).
19. Malhotra S, Man SF, Sin DD. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin. Emerg. Drugs 11(2), 275-291 (2006).
20. 1. Am. J. Respir. Crit. Care Med. 155(3), 852-857 (1997).
21. Di Stefano A, Turato G, Maestrelli P et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153(2), 629-632 (1996).
22. Pesci A, Balbi B, Majori M et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 12(2), 380-386 (1998).
23. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 153(2), 530-534 (1996).
24. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br. Med. J. (Clin. Res. Ed.) 291(6504), 1235-1239 (1985).
25. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 160(3), 893-898 (1999).
26. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med. 160(5 Pt 2), S49-S52 (1999).
27. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J. Clin. Invest. 85(3), 682-689 (1990 .
28. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am. J. Respir. Cell Mol. Biol. 20(4), 729-736 (1999).
29. Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am. J. Respir. Cell Mol. Biol. 20(6), 1100-1102 (1999).
30. + T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-α: relative insensitivity to Fas ligand. Am. J. Respir. Cell Mol. Biol. 20(5), 849-858 (1999).
31. Kwon OJ, Au BT, Collins PD et al. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am. J. Physiol. 267(4 Pt 1), L398-L405 (1994).
32. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. J. Respir. Crit. Care Med. 156(2 Pt 1), 341-357 (1997).
33. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336(15), 1066-1071 (1997).
34. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107(11), 1514-1519 (2003).
35. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59(7), 574-580 (2004).
36. Broekhuizen R, Grimble RF, Howell WM et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1β-511 single nucleotide polymorphism. Am. J. Clin. Nutr. 82(5), 1059-1064 (2005).
37. Haskard DO. Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand. J. Rheumatol. 33(5), 281-292 (2004).
38. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 311(7), 421-425 (1984).
39. Lotvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir. Med. 94(Suppl. E), S6-S10 (2000).
40. Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164(5), 778-784 (2001).
41. Mahler DA, Donohue JF. Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115 (4), 957-965 (1999).
42. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 14(7), 775-783 (2005).
43. 2,-agonist, on isolated human bronchi. Eur. Respir. J. 29(3), 575-581 (2007).
44. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm. Pharmacol, Ther. 20(6), 740-749 (2007).
45. 2-agonist is effective and well tolerated on multiple dosing in patients with mild to moderate COPD. Eur. Respir. J. 26(Suppl. 49), S287 (2005).
46. 2-agonist, provides 24-hour bronchodilator efficacy in moderate-to-severe COPD. Proc. Am. Thorac. Soc. A117 (2006).
47. 2-agonist carmoterol. Eur. Respir. J. 28(Suppl. 50), S666 (2006).
48. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. Eur. Respir. J. 28(Suppl. 50), 666s (2006).
49. 2-agonist carmoterol given as a 2 μg qd dose; 8 days comparison with formoterol and placebo patients with persistent asthma. Eur. Respir. J. 28(Suppl. 50), S665 (2006).
50. Haeussermann S, Acerbi D, Brand P, Poli G, Meyer T. Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD. Eur. Respir. J. 28(Suppl. 50), S211 (2006).
51. Barnes P.J. Muscarinic receptor subtypes in airways. Eur. Respir. J. 6(3), 328-331 (1993).
52. Barnes PJ, Minette P, Maclagan J. Muscarinic receptor subtypes in airways. Trends Pharmacol. Sci. 9(11), 412-416 (1988).
53. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur. Respir. J. 8(9), 1506-1513 (1995).
54. Beeh KM, Welte T, Buhl R. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 69(4), 372-379 (2002).
55. Singh D, Corris PA, Tansley R. NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. Eur. Respir. J. 30(Suppl. 51), S527 (2007).
56. Kuna P, Vinkler I, Overend T, Snape S, Tansley R. Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur. Respir. J. 30(Suppl. 51), S354 (2007).
57. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48(3), 227-232 (1993).
58. MacNee W, Calverley PM. Chronic obstructive pulmonary disease. 7: management of COPD. Thorax 58(3), 261-265 (2003).
59. Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Corticosteroids. Chest 126(2 Suppl.), S138-S149 (2004).
60. Ito K, Ito M, Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352(19), 1967-1976 (2005).
61. Marwick JA, Kirkham PA, Stevenson CS et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am. J. Respir. Cell Mol. Biol. 31(6), 633-642 (2004).
62. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem. Biophys. Res. Commun. 315(1), 240-245 (2004).
63. Soriano JB, Sin DD, Zhang X et al. A pooled analysis of FEVI decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131(3), 682-689 (2007).
64. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 113(1), 59-65 (2002).
65. Kardos P, Keenan J. Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed 8(3), 54 (2006).
66. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch. Intern. Med. 162(22), 2527-2536 (2002).
67. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl J. Med. 338(7), 436-445 (1998).
68. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160(5 Pt 2), S72-S79 (1999).
69. de Boer WI. Perspectives for cytokine antagonist therapy in COPD. Drug Discov. Today 10(2), 93-106 (2005).
70. Nicholson GC, Tennant RC, Carpenter DC et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm. Pharmacol. Ther. 20(1), 52-59 (2007).
71. O'Connor BJ, Leakef B, Barnes P et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur. Respir. J. 30(Suppl. 51), S209 (2007).
72. Chapman RW, Minnicozzi M, Celly CS et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 322(2), 486-493 (2007).
73. Gonsiorek W, Fan X, Hesk D et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 322(2), 477-485 (2007).
74. Kanniess F, Khalileh S, Ludwig-Sengpiel A et al. SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects. Eur. Respir. J. 30(Suppl. 51), S209 (2007).
75. Taylor PC. Anti-TNFα therapy for rheumatoid arthritis: an update. Intern. Med. 42(1), 15-20 (2003).
76. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175(9), 926-934 (2007).
77. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 172(4), 465-469 (2005).
78. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. 2(9), 736-746 (2003).
79. Suissa S, Ernst P, Hudson M. TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 21(1), 234-238 (2008).
80. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 58(7), 585-588 (2003).
81. Molfino NA. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration 72(1), 105-112 (2005).
82. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur. Respir. J. 15(2), 274-280 (2000).
83. Bech KM, Kornmann O, Buhl R, Culpitt SY, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123(4), 1240-1247 (2003).
84. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 122(1), 289-294 (2002).
85. Bailey WC, Tashkin DP. Pharmacologic therapy: novel approaches for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4(7), 543-548 (2007).
86. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470), 1552-1560 (2005).
87. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363(9410), 731-733 (2004).
88. Hansel TT, Kharitonov SA, Donnelly LE et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 17(10), 1298-1300 (2003).
89. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 294(3), L478-L488 (2007).
90. Culpitt SV, Rogers DF, Fenwick PS et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58(11), 942-946 (2003).
91. Manning CD, Burman M, Christensen SB et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. 128(7), 1393-1398 (1999).
92. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485), 563-571 (2005).
93. Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62(12), 1081-1087 (2007).
94. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbrocker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176(2), 154-161 (2007).
95. Molfino NA, Mallikaarjun S, Zhang P, Shoaf S, Mitsui K. Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease. Eur. Respir. J. 28(Suppl. 50), S526 (2006).
96. Wise RA, Littner MR, Zhang P et al. Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 28(Suppl. 50), S527 (2006).
97. Barnes PJ, Adcock IM. NF-KB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol. Sci. 18(2), 46-50 (1997).
98. McIntyre KW, Shuster DJ, Gillooly KM et al. A highly selective inhibitor of I KB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48(9), 2652-2659 (2003).
99. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96(5), 2304-2310 (1995).
100. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 55(2), 241-269 (2003).
101. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47(2-3), 185-201 (2000).
102. Underwood DC, Osborn RR, Bochnowicz S et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 279(5), L895-L902 (2000).
103. Williams JC, Falcone RC, Knee C et al. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am. Rev. Respir. Dis. 144(4), 875-883 (1991).
104. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177(2), 814-820 (1991).
105. Luisetti M, Sturani C, Sella D et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir. J. 9(7), 1482-1486 (1996).
106. Llewellyn-Jones CG, Lomas DA, Stockley RA. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax 49(6), 567-572 (1994).
107. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. 148(4 Pt 1), 1056-1060 (1993).
108. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 70(3), 163-182 (1996).
109. Joos GF, De Swert KO, Pauwels RA. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. 429(1-3), 239-250 (2001).
110. Bai TR, Zhou D, Weir T et al. Substance P (NK1)- and neurokinin A (NK2)- receptor gene expression in inflammatory airway diseases. Am. J. Physiol. 269(3 Pt 1), L309-L317 (1995).
111. Joos GF, Vincken W, Louis R et al. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir. J. 23(1), 76-81 (2004).
112. Hiller FC, Alderfer V, Goldman M. Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study. Respir. Med. 97(Suppl. A), S45-S52 (2003).
113. 2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir. Med. 97(Suppl. A), S23-S33 (2003).
114. Zhou Y, Shapiro M, Dong Q et al. A calcium-activated chloride channel blocker inhibits goblet Cell Metaplasia and mucus overproduction. Novartis Found. Symp. 248, 150-165 (2002).
115. Kitazaki T, Fukuda M, Soda H, Kohno S. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. Lung Cancer 49(1), 125-128 (2005).